Create a free Manufacturing.net account to continue

Mylan's Acquisition Costs Hurt Profit

Generic drugmaker said its profit fell 14 percent in the first quarter as acquisition and restructuring costs outpaced its growing sales.

PITTSBURGH (AP) -- Generic drugmaker Mylan Inc. said Thursday its profit fell 14 percent in the first quarter as acquisition and restructuring costs outpaced its growing sales.

Revenue from generic sales rose 8 percent to $1.24 billion, and specialty pharmacy revenue rose 21 percent to $101 million. Sales of generics in the Europe, Middle East and Africa rose 15 percent to $410.8 million, and in the Asia Pacific region, those sales climbed 31 percent to $282.3 million.

Mylan has increasingly become a global operator, buying a majority stake in Matrix Laboratories of India in early 2007. It moved into Europe, Africa, the Middle East, and Asia-Pacific by buying Merck KGaA's generics unit. In 2009 Mylan bought the rest of Matrix.

Yet generic revenue fell 5 percent in North America to $562.7 million and Mylan spent $12.1 million integrating recent acquisitions and restructuring its operations. That compares to a $4.4 million gain from special items a year ago.

Mylan said its profit slipped to $61.1 million, or 20 cents per share, from $71.3 million, or 23 cents per share. Revenue increased 7 percent, to $1.29 billion from $1.21 billion. Excluding one-time costs, Mylan said it earned 36 cents per share.

Analysts were expecting a profit of 34 cents per share and Mylan matched predictions for revenue, according to Thomson Reuters.

The company maintained its forecast of $1.50 to $1.70 per share in profit this year. Analysts expect $1.61 per share and $5.54 billion in revenue on average.

More in Supply Chain